Showing posts with label colistin. Show all posts
Showing posts with label colistin. Show all posts

Saturday, May 28, 2016

Study: Colistin-resistant bacteria may elude detection


Colistin antibiotics mode of action, uses and adverse effects

Colistin-susceptible Enterobacter cloacae can harbor resistant bacterial colonies that are missed by diagnostic testing, increase in number when exposed to colistin, and cause lethal infections, according to a study today in Nature Microbiology.

The authors say that multidrug-resistant Enterobacter species are a growing cause of hospital-acquired infections, with colistin used as a last-line treatment. With some bacterial infections, they add, antibiotic treatment fails in about 10% of cases even when the strain is classified as antibiotic-susceptible.

The 2014 "Review on Antimicrobial Resistance," compiled by the government of the United Kingdom and the Wellcome Trust, estimated that antibiotic-resistant infections will cause 10 million deaths each year by 2050. While the emergence of resistant bacterial strains is a growing problem, little is known about the causes of treatment failure in infections with pathogens that are classified as susceptible to antibiotics.

Rapid growth in presence of colistin

Researchers from the US Centers for Disease Control and Prevention (CDC) and multiple centers at Emory University, including the Emory Antibiotic Resistance Center, identified colonies of colistin-resistant E cloacae living in an E cloacae isolate that had been diagnosed as colistin-susceptible.

Most colonies (more than 90%) in the isolate, which was obtained from a renal transplant patient, were susceptible to a small dose of colistin (1 microgram [mcg] per milliliter [ml]). A small subpopulation, however, demonstrated significant resistance even in the presence of 500 mcg per ml of colistin, which is striking, given previous studies" findings that resistant E cloacae strains can be killed with 200 mcg per ml .

When the cultured isolate, dubbed "R/S" because of the coexisting resistant and susceptible strains, was exposed to colistin, the resistant subpopulation became predominant and increased to account for more than 80% of the isolate in 24 hours. The expansion of resistant bacteria was due to selection against the susceptible population in the first 2 hours of antibiotic exposure and rapid replication, the authors said.

Increases in the resistant E cloacae subpopulation were reversed when R/S was grown in an antibiotic-free environment, and proportions soon returned to pre-treatment levels. The rapid increase in the resistant population when exposed to colistin means that it is not a "persister"a population of resistant bacteria that can be subdued but not eliminated by antibiotics and can later lead to relapsebut rather a population with the ability to actually cause severe infection in the presence of colistin, the authors said.

Immune system role in resistant group"s behavior

Several factors are believed to contribute to the behavior of R/S"s resistant subpopulation, and chief among these is the immune system"s innate response to infection. When mice were infected with the R/S strain but not exposed to colistin, the resistant subpopulation increased from less than 10% to more than 80% of the strain within 48 hours, which suggests that the infection process plays a role in the resistant bacteria"s expansion.

Researchers determined that the natural antibacterials found in macrophages, which play a key role in early immune response to infection, were responsible for increasing the proportion of colistin-resistant E cloacae in mice. When macrophages were infected in vitro with the R/S strain, the resistant subpopulation grew to account for 40% of the isolate within 2 hours, the authors said.

When mice infected with the R/S strain were treated with colistin, bacterial levels increased tenfold, yet the effect of treatment appeared to depend on when antibiotics were administered. Colistin reduced total levels of E cloacae when given at the time of infection, but had the opposite effect, prompting the proportional increase of resistant colonies and an overall increase in bacterial load, when administered only 4 hours after infection.

Mice with depleted macrophages were receptive to colistin and had lower bacterial levels at 4 hours post-infection, highlighting the important role that host immune response plays in treatment failure. When mice were given a lethal dose of the R/S strain, colistin treatment led to death in 100 hours, in contrast to mice that survived when treated with colistin after receiving lethal doses of a susceptible E cloacae strain.

"Persisters are kept at bay by antibiotic treatment and form a reservoir that can cause relapse, but the colistin-resistant subpopulation described has the ability to cause acute infection and lethality during the course of antibiotic treatment," the authors said.

Gene expression and clonal heteroresistance

Because numbers of the resistant subpopulation rose and fell depending on the presence of colistin, resistance is likely due to differences in gene expression rather than to a stable mutation, the authors said.

They found that the R/S strain showed upregulation of genes associated with producing the histidine kinase Pho-Q, which has previously been implicated in resistance to polymixin antibiotics, including colistin. In the absence of Pho-Q, the R/S strain showed susceptibility to colistin, and the resistant subpopulation did not dominate the susceptible colonies.

The authors refer to the phenomenon as "clonal heteroresistance," which "in addition to mediating lethal infection in the presence of antibiotic, can also go undetected and cause unexplained treatment failure during in vivo infection."

Strain missed by diagnostic tests

Researchers cultured a separate R/S E cloacae isolate with a substantially smaller resistant subpopulation consisting of about 1 in 10,000 bacteria out of the total isolate. The strain was initially classified as drug-susceptible, yet the subpoulation expanded when exposed to colistin and during macrophage infection.

The resistant subpopulation was not detected by epsilometer test (Etest), which is used to determine susceptibility, and the isolate was classified as colistin-susceptible by a clinical microbiology laboratory when cultured, the report says.

Given the potentially catastrophic effects of colistin treatment for R/S E cloacae strains, there is an urgent need for sensitive and accurate diagnostic tests that can detect small proportions of resistant bacteria harbored by drug-susceptible colonies, the authors said.

"These data demonstrate the impact of an antibiotic resistant subpopulation in mediating a lethal influence in the presence of high-dose antibiotic treatment," the authors said.

May 9 Nat Microbiol study

Source: http://www.cidrap.umn.edu/news-perspective/2016/05/study-colistin-resistant-bacteria-may-elude-detection

Continue Reading ..

First discovery in United States of colistin resistance in a human E. coli infection


What causes antibiotic resistance? - Kevin Wu

The Multidrug Resistant Organism Repository and Surveillance Network (MRSN) at the Walter Reed Army Institute of Research (WRAIR) characterized a transferrable gene for colistin resistance in the United States that may herald the emergence of truly pan-drug resistant bacteria.

Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the best tool available to treat multidrug resistant bacteria because bacteria were not exchanging genes for its resistance. This latest discovery shows that colistin may be losing its effectiveness in antimicrobial therapy. Now, bacteria may be exchanging resistance genes for colistin.

Alarms sounded in the microbiology community in late 2015 when the first transferrable gene for colistin-resistance was identified in China. Since the report, the global health community has monitored and searched for the occurrence of this gene in the food supply and in humans. This colistin-resistance gene has been reported in Europe and Canada and, as of now, is reported in the U.S.

A clinical sample from a urinary tract infection was collected from a patient in a military treatment facility in Pennsylvania. The sample was sent to the Walter Reed National Military Medical Center (WRNMMC) where colistin susceptibility was tested. The results showed that no safe dosage of colistin would be effective to treat such a bacterial infection. WRNMMC recognized colistin-resistance and sent a sample to WRAIR"s MRSN for sequencing, which identified the colistin-resistant gene, mcr-1.

"Colistin is one of the last efficacious antibiotics for the treatment of highly resistant bacteria. The emergence of a transferable gene that confers resistance to this vital antibiotic is extremely disturbing. The discovery of this gene in the U.S. is equally concerning, and continued surveillance to identify reservoirs of this gene within the military healthcare community and beyond is critical to prevent its spread," reported Dr. Patrick McGann, MRSN, WRAIR.

Through intergovernmental communication, it was learned the CDC and USDA are also reporting a swine intestinal infection with a single mcr-1 positive E. coli strain. While there is no evidence that links these recent findings, the evidence of the strain in the U.S. is a public health concern. The gene is transferrable to other bacteria, which could worsen the current global crisis of antimicrobial resistance.

An urgent public health response is underway to contain and prevent potential spread of mcr-1. Active surveillance of multidrug resistant organisms (MDROs), such as mcr-1, allows for earlier and more accurate identification of originating sources. The collection and storage of isolates and samples in the MRSN"s growing repository helps researchers identify trends in resistance and prevalence of MDROs and provide best practices for medical providers. The repository also enables them to compare isolates from previous occurrences to better respond to future findings. Recognized as a model program by the White House, the MRSN is a key component of the National Action Plan for Combating Antibiotic Resistant Bacteria (CARB).

With the MRSN"s archive, this isolate will be archived for future studies to identify new countermeasures. "Through our surveillance system, we have the unique ability to coordinate source information with susceptibility and sequencing data, and if need be, go back to understand changes in infecting organisms to best treat infection and track emerging multidrug resistant organisms," COL Emil Lesho, Director of the MRSN, WRAIR.

This finding has been published by Antimicrobial Agents and Chemotherapy (AAC) of the American Society for Microbiology (ASM).

Story Source:

The above post is reprinted from materials provided by The U.S. Military HIV Research Program (MHRP). Note: Materials may be edited for content and length.

Source: http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNHFp6ijTu_wqqgPvqa4WZ3sPGtEjg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779119825936&ei=G4dKV7DONMPQpweG-J_ADw&url=https://www.sciencedaily.com/releases/2016/05/160526152033.htm

Continue Reading ..